p73-dependent induction of 14-3-3σ increases the chemo-sensitivity of drug-resistant human breast cancers

Biochemical and Biophysical Research Communications

Volumn 347, Issue 1, 2006, Pages 327-333

  Sang, Meixiang ^a,b   Li, Yuanyuan ^a   Ozaki, Toshinori ^a   Ono, Sayaka ^c   Ando, Kiyohiro ^a   Yamamoto, Hideki ^a   Koda, Tadayuki ^c   Geng, Cuizhi ^b   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c HISAMITSU PHARMACEUTICAL CO INC   (Japan)

Author keywords

14 3 3 ; Adriamycin; Breast cancer; p53; p73

Indexed keywords

DOXORUBICIN; LUCIFERASE; PROTEIN 14 3 3; PROTEIN 14 3 3 SIGMA; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STABILITY; REPORTER GENE; SEQUENCE HOMOLOGY; TRANSACTIVATION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EXONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33745743332     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.079     Document Type: Article

References (30)

1. Vousden K.H., and Lu X. Live or death: the cells response to p53. Nat. Rev. Cancer 2 (2002) 594-604
2. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
3. Oda E., Ohki R., Murasawa H., nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
4. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7 (2001) 673-682
5. Oda K., Arakawa H., Tanaka T., matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., and Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46- phosphorylated p53. Cell 102 (2000) 849-862
6. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
7. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Kato I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M., and Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4 (1998) 839-843
8. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
9. Melino G., De Laurenzi V., and Vousden K.H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2 (2002) 605-615
10. Ozaki T., and Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 96 (2005) 729-737
11. Ikawa S., Nakagawara A., and Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 6 (1999) 1154-1161
12. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
13. Gallardo D., Drazan K.E., and McBride W.H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56 (1996) 4891-4893
14. Mukhopadhyay T., and Roth J.A. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14 (1997) 379-384
15. Crawford L.V., Pim D.C., and Lamb P. The cellular protein p53 in human tumours. Mol. Biol. Med. 2 (1984) 261-272
16. Cattoretti G., Rilke F., Andreola S., D'Amato L., and Domenico D. p53 in breast cancer. Int. J. Cancer 41 (1988) 178-183
17. Moll U.M., Riou G., and Levine A.J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89 (1992) 7262-7266
18. Prasad G.L., Valverius E.M., McDuffie E., and Cooper H.L. Complementary DNA cloning of a novel epithelial cell marker protein, Hme1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ. 3 (1992) 507-513
19. Ferguson A.T., Evron E., Umbricht C.B., Pandita T.K., Chan T.A., Hermeking H., Marks J.R., Lambers A.R., Futreal P.A., Stampfer M.R., and Sukumar S. High frequency of hypermethylation at the 14-3-3s locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. USA 97 (2000) 6049-6054
20. Laronga C., Yang H.Y., Neel C., and Lee M.H. Association of the cyclin-dependent kinases and 14-3-3σ negatively regulates cell cycle progression. J. Biol. Chem. 275 (2000) 23106-23112
21. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., and Vogelstein B. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1 (1997) 3-11
22. Yang H.-Y., Wen Y.-Y., Chen C.-H., Lozano G., and Lee M.-H. 14-3-3σ positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 23 (2003) 7096-7170
23. Ando K., Ozaki T., Yamamoto H., Furuya K., Hosoda M., Hayashi S., Fukuzawa M., and Nakagawara A. Polo-like linase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. 279 (2004) 25549-25561
24. Vayssade M., Haddada H., Faridoni-Laurens L., Tourpin S., Valent A., Benard J., and Ahomadegbe J.C. p73 functionally replaces p53 in adriamycin-treated, p53-deficient breast cancer cells. Int. J. Cancer 116 (2005) 860-869
25. Gray-Bablin J., Zalvide J., Fox M.P., Knickerbocker C.J., DeCaprio J.A., and Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA 93 (1996) 15215-15220
26. Ragnarsson G., Eiriksodottir G., Johannsdottir J.T., Jonasson J.G., Egilsson V., and Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer 79 (1999) 1468-1474
27. Yang H., Zhao R., and Lee M.-H. 14-3-3σ, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol. Cancer Ther. 5 (2006) 253-260
28. Rossi M., De Laurenzi V., Munarriz E., Green D.R., Liu Y.C., Vousden K.H., Cesareni G., and Melino G. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24 (2005) 836-848
29. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G., Balsano C., and Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9 (2002) 175-186
30. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410